BioCardia Q1 net loss narrows to $2.3M; CardiAMP HF 86% mortality reduction in subgroup

BioCardia, Inc.

Q1 net loss $2.3M vs $3.5M YoY; revenue $55K; operating cash burn $1.5M (improved from $2.6M).
CardiAMP HF interim: 86% relative risk reduction in mortality for elevated NTproBNP subgroup; final data Q4 2024.
Confirmatory Phase III HF II trial activated Q1; 250-patient, >90% powered, enrollment goal 2 years.
CardiALLO low dose cohort completed with no adverse events; partnership with StemCardia for Phase I/II.
Morph-DNA steerable sheath FDA submission on track for Q2 2024; expected approval Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioCardia, Inc. reported first quarter of 2024 results: revenue approximately $55,000.

Period: first quarter of 2024
Revenue: approximately $55,000
Result: reported results

Exact text from the filing

Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-016616

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.